NASDAQ:LMNX - Luminex Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $37.00
  • Forecasted Upside: 0.03 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$36.99
+0.30 (1.20%)
Get New Luminex Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LMNX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LMNX

Analyst Price Target is $37.00
▲ +0.03% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Luminex in the last 3 months. The average price target is $37.00, with a high forecast of $37.00 and a low forecast of $37.00. The average price target represents a 0.03% upside from the last price of $36.99.

This chart shows the closing price for LMNX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 3 contributing investment analysts is to hold stock in Luminex. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
5/1/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/30/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/26/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
4/26/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
7/25/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
9/23/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
10/23/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/19/2021BTIG ResearchReiterated RatingBuy ➝ NeutralN/A
4/19/2021Piper SandlerReiterated RatingOverweight ➝ Neutral$38.00 ➝ $37.00N/A
4/13/2021Piper SandlerDowngradeOverweight ➝ Neutral$38.00 ➝ $37.00Low
4/13/2021BTIG ResearchDowngradeBuy ➝ NeutralLow
4/12/2021JPMorgan Chase & Co.UpgradeUnderweight ➝ NeutralLow
8/18/2020Piper SandlerInitiated CoverageBuy$38.00Low
11/11/2019BTIG ResearchLower Price TargetBuy$32.00Low
9/27/2019JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$23.00 ➝ $21.00Low
5/7/2019William BlairReiterated RatingMarket PerformLow
11/6/2018CitigroupLower Price TargetNeutral ➝ Neutral$34.00 ➝ $33.00High
8/7/2018Jefferies Financial GroupReiterated RatingHold$27.00High
7/23/2018CitigroupBoost Price TargetNeutral ➝ $33.58$23.00 ➝ $34.00Low
5/8/2018BTIG ResearchSet Price TargetBuy$26.00High
5/7/2018Deutsche Bank AktiengesellschaftUpgradeSell ➝ Hold$22.00High
2/13/2018William BlairReiterated RatingMarket PerformLow
1/5/2018BTIG ResearchInitiated CoverageBuy ➝ Buy$24.00High
10/20/2017Jefferies Financial GroupReiterated RatingHold$21.00N/A
6/9/2017Jefferies Financial GroupReiterated RatingHold$21.00Low
5/2/2017Jefferies Financial GroupBoost Price TargetHold$20.00 ➝ $21.00Medium
2/14/2017Jefferies Financial GroupReiterated RatingHold$20.00N/A
2/7/2017Piper Jaffray CompaniesLower Price TargetNeutral$20.00 ➝ $19.00N/A
2/7/2017William BlairReiterated RatingMarket PerformN/A
1/18/2017Deutsche Bank AktiengesellschaftReiterated RatingSell$18.00N/A
11/1/2016William BlairReiterated RatingMarket PerformN/A
(Data available from 10/23/2016 forward)

News Sentiment Rating

0.25 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/27/2021
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/26/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/26/2021
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/25/2021
  • 1 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/25/2021
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/24/2021
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/23/2021
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/23/2021

Current Sentiment

  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Luminex logo
Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; and TDAS, an analysis program designed for development and optimization of nucleic acid assays. The company also provides xTAG assays and products to identify the causative agent for respiratory and gastrointestinal infections, as well as IVD kits for cystic fibrosis genotyping and pharmacogenetic assays used to profile genetic mutations related to drug metabolism; ARIES system, a sample to answer real-time PCR platform; SYNCT data management software solutions; and ARIES cassettes that are self-contained assay consumables, such as ARIES HSV 1&2 Assay, ARIES Flu A/B & RSV Assay, ARIES Group B Streptococcus Assay, ARIES Group A Strep Assay, ARIES Bordetella Assay, ARIES Norovirus Assay, ARIES C. difficile Assay, ARIES MRSA Assay, and SARS-CoV-2 Assay. In addition, it offers VERIGENE system, a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market; VERIGENE test cartridges; Amnis FlowSight imaging flow cytometers; Amnis ImageStream Mark II imaging flow cytometers; Amnis CellStream for cell and particle analysis; Guava easyCyte benchtop flow cytometers; Muse cell analyzers; and IDEAS, an image analysis software. Luminex Corporation was founded in 1995 and is based in Austin, Texas.
Read More

Today's Range

Now: $36.99
Low: $36.99
High: $36.99

50 Day Range

MA: $36.90
Low: $36.66
High: $37.01

52 Week Range

Now: $36.99
Low: $20.61
High: $41.69

Volume

N/A

Average Volume

873,093 shs

Market Capitalization

$1.75 billion

P/E Ratio

72.53

Dividend Yield

1.08%

Beta

0.56

Frequently Asked Questions

What sell-side analysts currently cover shares of Luminex?

The following Wall Street analysts have issued reports on Luminex in the last year: BTIG Research, JPMorgan Chase & Co., and Piper Sandler.
View the latest analyst ratings for LMNX.

What is the current price target for Luminex?

1 Wall Street analysts have set twelve-month price targets for Luminex in the last year. Their average twelve-month price target is $37.00, suggesting a possible upside of 0.0%. Piper Sandler has the highest price target set, predicting LMNX will reach $37.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $37.00 for Luminex in the next year.
View the latest price targets for LMNX.

What is the current consensus analyst rating for Luminex?

Luminex currently has 3 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in LMNX, but not buy more shares or sell existing shares.
View the latest ratings for LMNX.

How do I contact Luminex's investor relations team?

Luminex's physical mailing address is 12212 TECHNOLOGY BLVD, AUSTIN TX, 78727. The medical instruments supplier's listed phone number is 512-219-8020 and its investor relations email address is [email protected] The official website for Luminex is www.luminexcorp.com.